Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)

NCT02108860 is registered in ClinicalTrials.gov with University of South Florida as lead sponsor.

NCT NCT02108860
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02108860 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Abatacept (CTLA4-Ig) for the Treatment of Relapsing, Non-Severe, Granulomatosis With Polyangiitis (Wegener's) (ABROGATE)
Lead sponsor
University of South Florida
Phase
Phase 3
Overall status
Completed
Start date
April 25, 2015
Completion date
December 20, 2023
Enrollment
65 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

anca-associated vasculitis, granulomatosis with polyangiitis, granulomatosis with polyangiitis (wegener's), wegener's granulomatosis